Chemotherapy and Mental Side Effects

For many years now there has been chatter in the cancer community that anti-cancer treatment like chemotherapy results in a mental fogginess that many people feel they cannot overcome. This experience is referred colloquially as chemobrain.

Patients will often report that following chemotherapy treatment they lose a bit of their cognitive edge; they feel a little more confused and they don't feel as sharp as they used to.

Problems

People tend to lose an edge or two to their mental clarity as they get older, and this simple fact may be partly responsible for chemobrain, and it is one that is often overlooked by patients and health professionals alike. After all, how often do we have our cognitive abilities truly tested so that we can test them again with the same test months or a year later? In other words, lacking a cognitive baseline, it is very hard to know objectively if a person's cognition or memory skills have changed following cancer therapy.

According to one of the leading experts on this phenomenon, Patricia Ganz, MD, not all cancer patients face the same risk of experiencing chemobrain. Her research has uncovered the reality that patients at risk for chemobrain include children and adults treated for brain tumors with whole-brain radiation, as well as leukemia and lymphoma patients who received intraspinal chemotherapy.

Other research suggests that some chemotherapy drugs affect the brain's ability to regenerate brain cells, which could be a primary driving force behind chemobrain. However, this research is ongoing and lacks enough evidence to assert anything one way or the other.

Solutions

Patients concerned about chemobrain can look into clinical trials that might help to create a baseline for them before they begin treatment, and then be tested against that baseline later. They can also begin mental exercises, even simple ones like crossword puzzles, prior to treatment in an effort to stay sharp. While there are few good answers out there regarding this problem, there are many smart minds at work on it.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap